Kailera Therapeutics, Inc.
For the period ended Nov 4, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 4, 2026 · Filed Nov 4, 2026
Use the contents to explore the available documents and sections.
KLRA$12.97+6.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (UNAUDITED)
(UNAUDITED)
| September 30,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $106,537 | $160,267 |
| Marketable securities | 794,917 | 385,789 |
| Prepaid expenses and other current assets | 18,302 | 11,481 |
| Total current assets | 919,756 | 557,537 |
| Property and equipment, net | 1,652 | 1,955 |
| Restricted cash | 761 | 761 |
| Long-term marketable securities | 136,187 | 106,672 |
| Non-current clinical deposits | 14,129 | 12,185 |
| Operating lease right-of-use assets | 9,630 | 10,463 |
| Other non-current assets | 63 | 2,721 |
| Total assets | $1,082,178 | $692,294 |
| Liabilities, convertible preferred stock and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $9,434 | $7,529 |
| Accrued expenses and other current liabilities | 31,590 | 37,836 |
| Operating lease liabilities, current | 1,092 | 1,040 |
| Total current liabilities | 42,116 | 46,405 |
| Operating lease liabilities, non-current | 8,879 | 9,713 |
| Other non-current liabilities | 67 | 270 |
| Total liabilities | 51,062 | 56,388 |
| Commitments and contingencies | ||
| Convertible preferred stock: | ||
| Series A convertible preferred stock | — | 390,306 |
| Series B convertible preferred stock | — | 602,058 |
| Stockholders’ equity (deficit): | ||
| Preferred stock | — | — |
| Common stock | — | — |
| Additional paid-in capital | 1,689,358 | 11,981 |
| Accumulated other comprehensive (loss) income | (3,737) | 229 |
| Accumulated deficit | (654,505) | (368,668) |
| Total stockholders’ equity (deficit) | 1,031,116 | (356,458) |
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $1,082,178 | $692,294 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.